Skip to main content

This job has expired

You will need to login before you can apply for a job.

Sr Medical Advisor-IO Translational Lead

Employer
Eli Lilly and Company
Location
New York, NY, United States
Start date
May 18, 2019

View more

Job Details

At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, Indiana. Our 39,000 employees around the world work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to our communities through philanthropy and volunteerism. We give our best effort to our work, and we put people first. We're looking for people who are determined to make life better for people around the world.

Responsibilities
The Oncology R&D organization is in the midst of a transformation agenda that will rely heavily on our competitiveness in Immuno-oncology . The IO Translational lead will lead translational efforts for the IO clinical development team, and will serve as a critical interface with the IO research and clinical teams as well as with our central diagnostics group . The ideal candidate will bring a strong sense of urgency around the unmet patient need, will push for speed and agility in all translational efforts, and will bring a collaborative spirit to enable disparate functions to drive a shared agenda. This role is a key member of the IO Lead Team, reporting to the VP Immuno-Oncology Medical Development and head of translational oncology research.
Key Deliverables

  • Provide management support and leadership for projects to evaluate biomarkers of immunomodulation in human specimens from internal clinical trials and external collaborations.
  • Lead a translational team comprising team members working in genomic evaluations, immunohistochemistry, FACs, and other immunoprofiling modalities to help guide research into resistance mechanisms and combination strategies for our IO franchise
  • Drive development of ex-vivo human model systems to evaluate novel IO targets and IO pipeline assets
  • Prioritize and manage multi-asset initiatives within Lilly for evaluation of potential biomarkers of response and/or resistance across IO programs and IO combination studies.
  • Accountable for working with research IT to guide development of centralized database of clinical outcomes data with relevant genomic, immunohistochemistry, cytokine, and other immune marker datasets from Lilly public private partnerships (ImmuCan) and Lilly IO trials that can be used to inform translational work for other IO programs.
  • Advise individual product teams develop priorities in specimen collection and evaluations from clinical trials required to inform the development of combination immunotherapy.
  • Lead development of pharmacodynamic assays to be used as part of clinical development
  • Responsible for leading collaboration efforts (industry and academic) around evaluation of assets in human specimens (short-term/long-term cultures and fixed specimens).
  • Work directly with the Diagnostics, Preclinical, and Clinical Immuno-Oncology teams to evaluate potential collaborations, analyses, and gaps specific to asset development in the immune-oncology space, particularly in settings that may not be as responsive to monotherapy with PD-1/PD-L1 inhibitors.

49699BR

Basic Qualifications

  • Medical Doctor or Doctor of Osteopathy. Must be board eligible or certified in a medical specialty or have completed the comparable level of post-medical school clinical training relevant to the country of hiring. U.S. trained physicians must have achieved board eligibility or certification. Foreign medical graduates in U.S. based jobs, who are not U.S. board eligible or certified may be hired directly for employment in the U.S. at the discretion of the Chief Medical Officer.
  • Non-U.S. trained physicians must have completed education and training at a medical school that meets the requirements of the Liaison Committee on Medical Education (LCME). For the recognized list of foreign medical schools and the disapproved list, see http://www.in.gov/pla/2799.htm

 


Additional Skills/Preferences

 

 

  • Experience in immune-oncology drug development; hematopathology; or immune biomarker development preferred.
  • MD PhD preferred
  • Industry experience preferred
  • Effective communication, collaboration and partnering skills

 


Additional Information
Lilly is an EEO/Affirmative Action Employer and does not discriminate on the basis of age, race, color, religion, gender, sexual orientation, gender identity, gender expression, national origin, protected veteran status, disability or any other legally protected status

 

Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit. 

Company info
Location
893 S Delaware St
Indianapolis
Indiana
46285
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert